-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

634.O2.6 634. Myeloproliferative Syndromes: Clinical: Translational Science in MPN— Hitting the Mark

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Biological, AML, Adult, apoptosis, Diseases, Non-Biological, Therapies, Bone Marrow Failure, chemical interactions, Biological Processes, MPN, Technology and Procedures, Polycythemia vera, Cell Lineage, cytogenetics, thrombocythemia, Study Population, Clinically relevant, genomics, Myeloid Malignancies, pharmacology, TKI, molecular testing, molecular interactions, pathways, signal transduction
Sunday, December 6, 2020: 9:30 AM-11:00 AM
Moderators:
Vikas Gupta, MD, FRCP, FRCPath, The Princess Margaret Cancer Centre and Gabriela S. Hobbs, MD, Massachusetts General Hospital
Disclosures:
Hobbs: Merck: Research Funding; Incyte: Research Funding; Bayer: Research Funding; Constellation: Honoraria, Research Funding; Jazz: Honoraria; Novartis: Honoraria; Celgene/BMS: Honoraria.
9:30 AM

Claire Harrison, DM, FRCPath1, Joanna E Baxter, PhD2*, Rebecca H. Boucher, BSc, MSc, PhD3*, Thomas McKerrell, MD, PhD4,5,6*, Aimee Jackson, BSc, MSc3*, Rachel S Fletcher, PhD3*, Adam J. Mead, MD, PhD7, Steve Knapper, BMBCh, MRCP, FRCPath, DM8, Joanne Ewing, MD, PhD9*, Nauman M Butt, MD10*, Manish Jain, MBBS, MRCP, FRCpath11*, Sebastian Francis, MBChB, FRCPath, MD12*, Fiona J Clark, FRCP, FRCPath13*, Jason Coppell, MBBS14*, Mary Frances McMullin, MD FRCP, FRCPath15, Frances Wadelin, MB ChB, PhD, FRCPath16*, Srinivasan Narayanan, FRCP, FRCPath17*, Dragana Milojkovic18*, Mark W. Drummond, PhD, FRCPath19*, Mallika Sekhar, MBBS, MD20, Maike Paramor21*, James Roberts, BSc21*, Rachel Glover, BSc21*, Erica Harris, MSc21*, Luigi Grassi, PhD21*, Alba Rodriguez-Meira, PhD7,22,23*, Jason Carroll, PhD, FMedSci21*, José-Ezequiel Martín, PhD21*, Giuditta Corbizi Fattori, PhD21*, Zijian Fang, BSc21*, Anna L Godfrey, BMBCh, PhD6,21* and Simón Méndez-Ferrer, PhD21*

1Guy's and Saint Thomas' NHS Foundation Trust, London, United Kingdom
2University of Cambridge, Department of Haematology, Cambridge, United Kingdom
3Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom
4Department of Haematology, University of Cambridge, Cambridge, United Kingdom
5Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom
6Department of Clinical Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
7MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
8Division of Cancer & Genetics, Cardiff University, Cardiff, United Kingdom
9University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
10The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom
11Department of Haematology, St James University Hospital, Leeds, United Kingdom
12Haematology Department, Sheffield Teaching Hospitals NHS trust, Sheffield, United Kingdom
13Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
14Royal Devon and Exeter Hospital, Exeter, Exeter, United Kingdom
15Centre for Medical Education, Queens University, Belfast, United Kingdom
16Nottingham University Hospital, Nottingham, United Kingdom
17Department of Haematology, University Hospital Southampton NHSFT, Southampton, United Kingdom
18Imperial College Healthcare NHS Trust, London, United Kingdom
19Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
20University College Hospital London, London, United Kingdom
21University of Cambridge, Cambridge, United Kingdom
22MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
23MRC Centre for Computational Biology, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

9:45 AM

Clemence Marcault1*, Lin-Pierre Zhao, MD2*, Rafael Daltro De Oliveira, MD2*, Juliette Soret, MD3*, Nicolas Gauthier, MD2*, Emmanuelle Verger, PhD4,5*, Nabih Maslah, PharmD5,6*, Blandine Roux, MSc7*, Nathalie Parquet, MD8*, Christine Dosquet, MD5*, Delphine Rea, MD, PhD8, Jean-Marc Zini8*, William Vainchenker9*, Emmanuel Raffoux, MD8*, Stephane Giraudier, MD, PhD5,6*, Bruno Cassinat, PharmD, PhD5,10*, Jean-Jacques Kiladjian2,7 and Lina Benajiba, MD, PhD2,11*

1Saint-Louis, Nice, France
2Université de Paris, Clinical Investigations Center, Saint-Louis hospital, APHP, Paris, France
3Centre d'Investigations Cliniques, Hôpital Saint-Louis; Assistance Publique – Hôpitaux de Paris; Université de Paris, Paris, France
4INSERM UMR 1131, Saint-Louis Research Institute, Paris, France
5Université de Paris, Cellular biology Department, Saint-Louis hospital, APHP, Paris, France
6UMRS_1131, Inserm, Université de Paris, Institut de recherche Saint-Louis, Paris, France
7INSERM UMR 944, Saint-Louis Research Institute, Paris, France
8Université de Paris, Hematology department, Saint-Louis hospital, APHP, Paris, France
9Gustave Roussy, Villejuif, France
10Institut de Recherche St Louis, Université de Paris, INSERM U1131, Paris, France
11APHP, INSERM U944, Institute of Hematology - St Louis Hospital, PARIS, France

10:00 AM

Franco Castillo Tokumori, MD1*, Chetasi Talati, MD2, Najla E. Al Ali2, David A. Sallman, MD3, Seongseok Yun, MD, PhD2, Kendra L. Sweet, MD, MS2*, Eric Padron, MD4, Jeffrey E. Lancet, MD5, Rami Komrokji, MD6 and Andrew T. Kuykendall, MD2

1Department of Internal Medicine, University of South Florida, Tampa, FL
2Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
3H. Lee Moffitt Cancer Center, Tampa, FL
4Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
5Department of Malignant Hematology, H. Lee Moffitt Cancer Ctr. & Rsrch. Institute, Tampa, FL
6Moffitt Cancer Center, Tampa, FL

10:15 AM

Jason Gotlib, MD, MS1, Deepti H. Radia, MRCPI, FRCPath2*, Tracy I. George, MD3, William A Robinson, MD, PhD4*, Albert T. Quiery, MD5, Mark W. Drummond, PhD, FRCPath6*, Prithviraj Bose, MD7, Elizabeth O. Hexner, MD8*, Elliott F. Winton, MD9, Hans-Peter Horny, Prof, Dr10*, Meera Tugnait, PhD11*, Oleg Schmidt-Kittler, PhD11*, Erica K. Evans, PhD11*, Hui-Min Lin, PhD11*, Brenton G. Mar, MD, PhD11*, Michael W. Deininger, MD, PhD12 and Daniel J. DeAngelo, MD, PhD13

1Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA
2Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom
3ARUP Laboratories, University of Utah, Salt Lake City, UT
4UC Denver, Aurora, CO
5University of Michigan, Ann Arbor, MI
6Beatson Cancer Centre, Glasgow, United Kingdom
7Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
8Cell Therapy and Transplant, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
9Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA
10Institute of Pathology, Ludwig-Maximilians University, Munich, Germany
11Blueprint Medicines Corporation, Cambridge, MA
12Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT
13Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

10:30 AM

John Mascarenhas, MD1, Rami S. Komrokji, MD2, Michele Cavo3*, Bruno Martino, MD4*, Dietger Niederwieser, MD, PhD5, Andreas Reiter, MD6*, Bart L. Scott, MD7, Maria R. Baer, M.D.8, Ronald Hoffman, MD1, Olatoyosi Odenike, MD9, Laurie Sherman, BSN10, Souria Dougherty, BS, MBA10*, Faye Feller, MD10, Tymara Berry, MD10*, Libo Sun, PhD10*, Ying Wan, PhD10*, Aleksandra Rizo, MD, PhD10, Fei Huang, PhD10* and Jean-Jacques Kiladjian, MD, PhD11

1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
2H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
3Hematology/Oncology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy
4Grande Ospedale Metropolitano-G.O.M. Bianchi-Melacrino-Morelli, Reggio Calabria, Italy
5University Hospital Leipzig, Leipzig, Germany
6University Hospital Mannheim, Heidelberg University, Mannheim, Germany
7Fred Hutchinson Cancer Research Center, Seattle, WA
8Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD
9University of Chicago, Chicago, IL
10Geron Corporation, Parsippany, NJ
11Clinical Investigations Center, Saint-Louis hospital, Université de Paris, Paris, France

10:45 AM

John Mascarenhas, MD1, Rami Komrokji, MD2, Michele Cavo3*, Bruno Martino, MD4*, Dietger Niederwieser, MD, PhD5, Andreas Reiter, MD6*, Bart L. Scott, MD7, Maria R. Baer, M.D.8, Ronald Hoffman, MD1, Olatoyosi Odenike, MD9, Jacqueline Bussolari, PhD10, Eugene Zhu, PhD10*, Esther Rose, MD10*, Laurie Sherman, BSN11, Souria Dougherty, BS, MBA11*, Faye Feller, MD11, Libo Sun, PhD11*, Ying Wan, PhD11*, Aleksandra Rizo, MD, PhD11, Fei Huang, PhD11* and Jean-Jacques Kiladjian, MD, PhD12

1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
2Moffitt Cancer Center, Tampa, FL
3Seragnoli Institute of Hematology, University of Bologna, Bologna, Italy
4Grande Ospedale Metropolitano-G.O.M. Bianchi-Melacrino-Morelli, Reggio Calabria, Italy
5University Hospital Leipzig, Leipzig, Germany
6University Hospital Mannheim, Mannheim, Germany
7Fred Hutchinson Cancer Research Center, Seattle, WA
8Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD
9University of Chicago, Chicago, IL
10Janssen Research & Development, LLC, Raritan, NJ
11Geron Corporation, Parsippany, NJ
12Hopital Saint-Louis, Paris, France

*signifies non-member of ASH